Stereotaxis, Inc. has declared that it has obtained its 100th patent from the U.S. Patent and Trademark Office for "Method and Apparatus for Dynamic Magnetic Field Control Using Multiple Magnets." This patent represents the company’s enduring dedication in developing and maintaining its domination in providing robotic medical solutions.
P. Kaminski, President and CEO of Stereotaxis, has stated that their 100th patent indicates their company’s initiatives in securing their shareholder value and to provide novel technologies for enhancing the treatment possibilities for cardiac problems. He added that with this new position, they can provide pronounced clinical advantages for treatment applications including peripheral vascular, cardiovascular, neurovascular and ventricular tachycardia.
It was reported that Stereotaxis has been processing applications for receiving approval for additional 100 patents. The company has also obtained 30 non-U.S patents and in within a span of few months, their numbers are likely to be doubled, with their recent patent for Niobe Magnetic Navigation System. Current patents cover the areas of software automation, diagnostic integration, remote/robotic assisted cardiology procedures, information technology for patient/case management and therapeutic devices.
For the last two years, Stereotaxis featured in the top 10 list of IEEE Spectrum’s Patent Power Scorecard which evaluates globally significant patent portfolios. Most of the patents obtained by the company served as a beginning for a new medical solution and the rest of the patents have been innovatively utilized in partnerships with clients who are working on cardiology.